The verdict
Our read at a glance.
Whether follistatin's myostatin-blocking biology and early gene-therapy trials support the muscle-building claims made for gray-market follistatin peptide products.
- The signal
- Follistatin gene therapy has been tested in early trials for muscular dystrophies, with mixed and preliminary results. The injectable follistatin peptide products sold in the gray market are different from gene therapy and lack supporting human evidence. It is not approved for any use.
- The unknown
- Whether boosting follistatin safely produces meaningful muscle or functional benefit in any condition, and whether gray-market peptide products contain or do anything like what is claimed.
- Our read
- Real myostatin-blocking biology, no proven product. Follistatin is a legitimate research target with early gene-therapy trials, but the muscle-building peptide products sold online are unproven and of uncertain identity, and neither path is approved.
The mechanism
How it works.
Follistatin is a natural protein that binds and neutralizes myostatin and related activins, the signals that normally tell muscle to stop growing. When those brakes are removed, muscle is freed to grow larger, which is the rationale behind both follistatin gene therapy for muscle-wasting disease and the injectable follistatin peptide products sold for muscle building. The gene-therapy version has only mixed early-trial data, and the gray-market peptide products have no supporting human evidence and are a different thing entirely.
Safety & regulatory boundary
The consequential part.
Follistatin is not an approved drug. Gene-therapy approaches are investigational and carry the risks of gene therapy, while gray-market follistatin peptide products are research chemicals of uncertain identity and quality. Blocking myostatin broadly is not without risk. Gene-therapy research does not validate gray-market peptide claims, and these products are not the same as any investigational gene therapy.
What's next
What we're watching.
Later-phase gene-therapy trials in muscle disease, any safety findings, and product-identity findings for gray-market follistatin products.
Context
Why this is discussed.
Follistatin is a focal point for the idea of blocking myostatin to build muscle, which drives interest both in serious gene-therapy research and in the bodybuilding gray market.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · NA · RECRUITING · 2025-06-16
ClinicalTrials.gov · NA · ACTIVE_NOT_RECRUITING · 2024-02-11
ClinicalTrials.gov · NA · COMPLETED · 2020-06-24
ClinicalTrials.gov · NA · COMPLETED · 2022-07-14
ClinicalTrials.gov · PHASE1/PHASE2 · RECRUITING · 2026-02-28
ClinicalTrials.gov · NOT_YET_RECRUITING · 2026-04
ClinicalTrials.gov · NA · RECRUITING · 2025-07-01
ClinicalTrials.gov · PHASE1/PHASE2 · RECRUITING · 2026-03-31
Indexed literature (PubMed)12
Stefanakis K et al. · Metabolism · 2024
Esposito P et al. · Adv Clin Chem · 2022
Brown DW et al. · Cell · 2024
Nawaz A et al. · Nat Commun · 2022
Patel K · Int J Biochem Cell Biol · 1998
Zhang Y et al. · Cell Rep · 2024
Guignabert C et al. · Circulation · 2023
Guo S et al. · Nat Commun · 2023
Gonzalez-Gil AM et al. · Nutrients · 2020
Moore U et al. · Neuromuscul Disord · 2023
Rodino-Klapac LR et al. · Muscle Nerve · 2009
Nissinen TA et al. · FASEB J · 2021
Keep reading